Navigation Links
DRAXIS Responds to Trading
Date:3/17/2008

MONTREAL, March 17 /PRNewswire-FirstCall/ - DRAXIS Health Inc. (the "Company") (TSX: DAX) (NASDAQ: DRAX), in response to a request by securities regulators with respect to increased trading in its common stock, announced today that it is currently in exclusive discussions regarding a potential transaction that could lead to a sale of the Company. There can be no certainty at this stage that these discussions will continue or result in any agreement or transaction or result in pricing that will be acceptable either to the board of directors of the Company or to shareholders.

About DRAXIS Health Inc.:

DRAXIS Health, through its wholly owned operating subsidiary, DRAXIS Specialty Pharmaceuticals Inc., provides products in three categories: sterile products, non-sterile products and radiopharmaceuticals. Sterile products include liquid and freeze-dried (lyophilized) injectables plus sterile ointments and creams. Non-sterile products are produced as solid oral and semi-solid dosage forms. Radiopharmaceuticals are used for both therapeutic and diagnostic molecular imaging applications. Pharmaceutical contract manufacturing services are provided through the DRAXIS Pharma division and radiopharmaceuticals are developed, produced, and sold through the DRAXIMAGE division. DRAXIS employs approximately 500 staff in its Montreal facility.
For additional information please visit http://www.draxis.com

Caution Concerning Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and as contemplated under other applicable securities legislation. These statements can be identified by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "plan," "intend," "believe" or other similar words. These statements discuss future expectations concerning results of operations or financial condition or provide other forward-looking information. Our actual results, performance or achievements could be significantly different from the results expressed in, or implied by, those forward-looking statements. You should not place undue reliance on any forward-looking statement, which speaks only as of the date made.

These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors that could cause the Company's results or performance to differ materially from a conclusion, forecast or projection in the forward-looking statements include, but are not limited to:

- those related to discussions involving a potential transaction that

could lead to a sale of the Company;

- the achievement of desired clinical trial results related to the

Company's pipeline products;

- timely regulatory approval of the Company's products;

- the ability to comply with regulatory requirements applicable to the

manufacture and marketing of the Company's products;

- the Company's ability to obtain and enforce effective patents;

- the non-infringement of third party patents or proprietary rights by

the Company and its products;

- factors beyond our control that could cause interruptions in our

operations in our single manufacturing facility (including, without

limitation, material equipment breakdowns);

- reimbursement policies related to health care;

- the establishment and maintenance of strategic collaborative and

commercial relationships;

- the Company's dependence on a small number of key customers;

- the disclosure of confidential information by our collaborators,

employees or consultants;

- the preservation of healthy working relationships with the Company's

union and employees;

- the Company's ability to grow the business;

- the fluctuation of our financial results and exchange and interest

rate fluctuations;

- the adaptation to changing technologies;

- the loss of key personnel;

- the avoidance of product liability claims;

- the loss incurred if current lawsuits against us succeed;

- the volatility of the price of our common shares;

- market acceptance of the Company's products;

- factors described under "Outlook" in the Company's MD&A for the most

recent quarter; and

- the risks described in "Item 3. Key Information - Risk Factors" in the

Annual Report Form 20-F filed by the Company with the United States

Securities and Exchange Commission and which is also filed as the

Company's Annual Information Form with Canadian securities regulators.

For additional information with respect to certain of these and other factors, and relating to the Company generally, reference is made to the Company's most recent filings with the United States Securities and Exchange Commission (available on EDGAR at http://www.sec.gov) and the filings made by the Company with Canadian securities regulators (available on SEDAR at http://www.sedar.com). The forward-looking statements contained in this document represent the Company's expectations as at March 14, 2008. Unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DRAXIS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DRAXIS Health Reports Fourth Quarter and Year End Results
2. DRAXIS to Report Fourth Quarter and Year End 2007 Results on February 7th
3. DRAXIS Share Buyback Approved by TSX
4. DRAXIS Announces Application for Normal Course Issuer Bid
5. DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA
6. DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer
7. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
8. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
9. Maternal love: How a mothers brain responds to her infant
10. DuPont Responds to Spelter, W.Va. Lawsuit Rulings
11. Blue Cross of California Responds to Recent Media Coverage of Rescission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... First Choice Emergency Room ... Dr. Douglas J. Harrison, as the new Medical Director of its Sienna Plantation facility. ... Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, Area Medical ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... With low back pain afflicting 8 of ... what causes its kissing cousin – upper back pain. But this equally vexing condition stems ... options, according to Kaixuan Liu, MD, PhD , founder and president of Atlantic Spine ...
(Date:8/15/2017)... ... August 15, 2017 , ... Medicine is much more than ... who feels isolated. It’s developing relationships and thereby growing the mind. It’s finding ... MD, PhD, invited three renowned authors and academic leaders – and decades-long friends ...
(Date:8/15/2017)... ... 2017 , ... The Philadelphia Marathon and the American Association for Cancer Research ... the City’s commitment to improving the health of its citizens. Dedicated to preventing and ... healthy lifestyle as research shows this can help reduce the risk of cancer. ...
(Date:8/15/2017)... ... August 15, 2017 , ... The V Foundation for Cancer ... V Foundation Wine Celebration raised nearly $9 million for cancer research during a ... “Fund-A-Need” donations to support the study of BRCA mutation research in laboratories and ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and other ... up healthcare costs and threatening outcomes, were problems taken ... and IVD industry that support them, met this week. ... researcher said that drugs of abuse, procalcitonin and acute ... at the organization,s 69th meeting in San ...
Breaking Medicine Technology: